Español
Català
English
-

JOB OPPORTUNITY: We’re seeking candidates with a strong scientific background and professional experience to join our team as Investment Analyst. Apply now!

- INVIVO CAPITAL

JOB OPPORTUNITY / INTERNSHIP PROGRAM: We're seeking candidates to join us. Apply now!

- INVIVO CAPITAL

We are excited to announce that Claudio Santos has joined us as Entrepreneur in Residence to support our company creation activity in the technology transfer space

- INVIVO CAPITAL

JOB OPPORTUNITY: Our portfolio company Telomere Therapeutics is seeking candidates for a Project Manager position.

- EXPANSIÓN CATALUNYA

Genfit To Acquire Versantis

- INVIVO CAPITAL

We’re pleased to announce our second exit in less than a year: Genfit has announced it will acquire Versantis.

- EXPANSIÓN

Investing In Leading-Edge. Article published today in Expansión with the participation of Luis Pareras.

- INVIVO CAPITAL

JOB OPPORTUNITY: We’re seeking candidates with a strong scientific background to join our #internship opportunity. If you’re interested in learning how a #VC firm works, please apply!

- INVIVO CAPITAL

JOB OPPORTUNITY: We are looking for Controller candidates. If you are interested, please apply!

- INVIVO CAPITAL

Integra Therapeutics completes the €6-million seed round with the addition of Columbus Venture Partners

- INVIVO CAPITAL

Invivo Capital invests together with Kurma Partners, V-Bio Ventures and Omnes Capital in Corteria Pharmaceuticals, a French biotechnology company developing novel therapies for heart failure subpopulations with a high unmet clinical need.

- EXPANSIÓN CATALUÑA

Integra Tx raises 4.5 million from Advent, Invivo and Takeda

- INVIVO CAPITAL

Integra Tx secures €4.5-million in funding from Invivo Capital, Advent France Biotechnology and Takeda Ventures

- INVIVO CAPITAL

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology

- AJUNTAMENT DE BARCELONA

L’Ajuntament de Barcelona ha seleccionat Invivo Ventures FCR junt amb altres 5 fons de capital risc privats per participar en la iniciativa Barcelona Accelera

- Expansión (Ed. Cataluña)

Peptomyc capta 11,4 millones para iniciar un ensayo clínico en cáncer

- Minoryx Therapeutics

Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia

- INVIVO CAPITAL

Invivo boosts a gene therapy startup, Telomere Therapeutics, with 1.5 million

- INVIVO CAPITAL

Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology

- WEB CAPITAL RIESGO

Invivo Ventures, CDTI-Innvierte y la Fundación Josep Carreras cierran una ronda de €3,05 millones en OneChain Immunotherapeutics.

- CAPITAL RIESGO

Invivo Ventures, CDTI-Innvierte y la Fundación Josep Carreras cierran una ronda de financiación de 3.050.000€ en OneChain Immunotherapeutics

- INVIVO CAPITAL

The Josep Carreras Institute creates a spin-off to develop therapies for leukaemia based on CAR–T

- INVIVO CAPITAL

Telum Therapeutics raises € 4.1 million in its first round of financing to advance the development of new synthetic biology-based therapies for the treatment of infectious diseases caused by multi-resistant bacteria.

- PLANTA DOCE

Telum Therapeutics cierra una ronda de 4,1 millones liderada por Invivo Ventures

- WEBCAPITALRIESGO

Invivo Ventures invierte €1,5 millones en Gyala Therapeutics

- CAPITAL RIESGO

Invivo Ventures invierte 1,5 millones en Gyala Therapeutics

- Planta Doce

Gyala Therapeutics capta 1,5 millones de euros de Invivo Ventures

- INVIVO CAPITAL

A new cancer immune therapy spin-off of Hospital Clínic-IDIBAPS (Barcelona) secures a 1.5 million-euro investment from Invivo Ventures

- Expansión

Invivo Ventures invierte dos millones en la biotecnológica Pulmobiotics

- La Vanguardia

Pulmobiotics consigue dos millones para su inhalador

- Invivo Capital

Barcelona-based synthetic biology company secures two-million-euro investment

- Planta Doce

Invivo Ventures impulsa Pulmobiotics con una ‘inyección’ inicial de dos millones de euros

- Expansión Cataluña

Invivo invertirá 40 millones en el sector biomédico

- La Vanguardia

Invivo Ventures lidera una ronda de 1,5 millones

- Expansión Cataluña

El fondo Invivo Ventures debuta con una ronda de 1,5 millones en Arthex Biotech

- PlantaDoce

Invivo Ventures lidera una ronda de financiación de 1,5 millones en Arthex Biotech

- Expansión Cataluña

Invivo se estrena con un fondo biomédico de 40 millones

- PlantaDoce

Invivo Capital abre su fondo biomédico con 40 millones de euros

TOP